Drug therapies for Alzheimer’s disease (AD) have been evaluated in clinical trials over the
past 2 decades. Systematic reviews of AD drug trials can shed more light on the efficacy of …

Background: Canada and the United States have the highest levels of prescription opioid
consumption in the world. In an attempt to curb the opioid epidemic, a variety of interventions …

Past experience with a drug may modify the risk of adverse event associated with current
use of this drug. This effect was investigated empirically with a study on non-steroidal anti-…

Background Recently in France, primary pulmonary hypertension developed in a cluster of
patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), …

Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several
regulatory agencies, including the Food and Drug Administration. The tendency is now to …

In an era when the number of expedited and conditional review pathways for newly available
brand-name drugs and biosimilar medicines to treat serious and life-threatening diseases …

Objective: To compare the relative risks of serious gastrointestinal complications reported
with individual non-steroidal anti-inflammatory drugs. Design: Systematic review of controlled …

Objectives To investigate the relation between the risk of Alzheimer’s disease and exposure
to benzodiazepines started at least five years before, considering both the dose-response …

OBJECTIVES: To determine whether prevalent delirium is an independent predictor of
mortality in older patients seen in emergency departments (EDs) and discharged home without …

The objective of this article was to examine the possible association between benzodiazepine
use and the risk of dementia in the elderly. This was a nested case–control study set in …